214 related articles for article (PubMed ID: 26508513)
21. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
[TBL] [Abstract][Full Text] [Related]
22. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM
J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964
[TBL] [Abstract][Full Text] [Related]
23. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
24. Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements.
Bakshi RP; Breakey J; Manohar M; Jois B; Fuchs EJ; Marzinke MA
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):354-356. PubMed ID: 29258331
[TBL] [Abstract][Full Text] [Related]
25. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
Thurman AR; Schwartz JL; Brache V; Clark MR; McCormick T; Chandra N; Marzinke MA; Stanczyk FZ; Dezzutti CS; Hillier SL; Herold BC; Fichorova R; Asin SN; Rollenhagen C; Weiner D; Kiser P; Doncel GF
PLoS One; 2018; 13(6):e0199778. PubMed ID: 29953547
[TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.
Lu Y; Goti V; Chaturvedula A; Haberer JE; Fossler MJ; Sale ME; Bangsberg D; Baeten JM; Celum CL; Hendrix CW
Antimicrob Agents Chemother; 2016 Sep; 60(9):5379-86. PubMed ID: 27353269
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids.
Barreiros L; Cunha-Reis C; Silva EMP; Carvalho JRB; das Neves J; Sarmento B; Segundo MA
J Pharm Biomed Anal; 2017 Mar; 136():120-125. PubMed ID: 28073073
[TBL] [Abstract][Full Text] [Related]
28. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Thurman AR; Ouattara LA; Yousefieh N; Anderson PL; Bushman LR; Fang X; Hanif H; Clark M; Singh O; Doncel GF
Front Cell Infect Microbiol; 2023; 13():1130101. PubMed ID: 37153145
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
Valade E; Bouazza N; Lui G; Illamola SM; Benaboud S; Treluyer JM; Cobat A; Foissac F; De Sousa Mendes M; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Urien S; Ghosn J; Hirt D
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956420
[TBL] [Abstract][Full Text] [Related]
30. Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.
Herold BC; Dezzutti CS; Richardson BA; Marrazzo J; Mesquita PM; Carpenter C; Huber A; Louissaint N; Marzinke MA; Hillier SL; Hendrix CW
J Acquir Immune Defic Syndr; 2014 May; 66(1):65-73. PubMed ID: 24457633
[TBL] [Abstract][Full Text] [Related]
31. A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).
Hiruy H; Fuchs EJ; Marzinke MA; Bakshi RP; Breakey JC; Aung WS; Manohar M; Yue C; Caffo BS; Du Y; Abebe KZ; Spiegel HM; Rohan LC; McGowan I; Hendrix CW
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1098-108. PubMed ID: 26227279
[TBL] [Abstract][Full Text] [Related]
32. Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.
Richardson-Harman N; Hendrix CW; Bumpus NN; Mauck C; Cranston RD; Yang K; Elliott J; Tanner K; McGowan I; Kashuba A; Anton PA
PLoS One; 2014; 9(10):e111507. PubMed ID: 25350130
[TBL] [Abstract][Full Text] [Related]
33. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Moss JA; Butkyavichene I; Churchman SA; Gunawardana M; Fanter R; Miller CS; Yang F; Easley JT; Marzinke MA; Hendrix CW; Smith TJ; Baum MM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321
[TBL] [Abstract][Full Text] [Related]
34. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
Velloza J; Heffron R
Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
[TBL] [Abstract][Full Text] [Related]
35. Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.
Srinivas N; Cottrell M; Maffuid K; Prince HA; Nelson JAE; White N; Sykes C; Dellon ES; Madanick RD; Shaheen NJ; Gonzalez D; Kashuba ADM
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740561
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
Lade JM; To EE; Hendrix CW; Bumpus NN
EBioMedicine; 2015 Sep; 2(9):1145-52. PubMed ID: 26501112
[TBL] [Abstract][Full Text] [Related]
37. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
[TBL] [Abstract][Full Text] [Related]
38. Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.
Liu SN; Desta Z; Gufford BT
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):40-47. PubMed ID: 31749296
[TBL] [Abstract][Full Text] [Related]
39. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Leethochawalit M; Chiamwongpaet S; Curlin ME; Na-Pompet S; Warapronmongkholkul A; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Choopanya K;
AIDS; 2015 Apr; 29(7):819-24. PubMed ID: 25985403
[TBL] [Abstract][Full Text] [Related]
40. First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.
Friedland BA; Hoesley CJ; Plagianos M; Hoskin E; Zhang S; Teleshova N; Alami M; Novak L; Kleinbeck KR; Katzen LL; Zydowsky TM; Fernández-Romero JA; Creasy GW
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):489-496. PubMed ID: 27437826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
